Market Intelligence, ADME Progress, and High-Purity Reagents for Pharmacokinetic & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGT1A8 metabolic profiling and drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | UGT1A8 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View UGT1A8 Products |
| Gene Delivery | UGT1A8 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View UGT1A8 Products |
| Benchmark Ab | Anti-UGT1A8 Reference Antibody Recombinant positive control for expression profiling. |
View UGT1A8 Products |
| Validator | UGT1A8 siRNA Set For knockdown verification in metabolic assays. |
View UGT1A8 Products |
| Related Target A | UGT1A1 Hepatic metabolism homolog for selectivity screening. |
View UGT1A1 Products |
| Related Target B | CYP3A4 Phase I metabolic enzyme for comprehensive ADME profiling. |
View CYP3A4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity | UGT family homolog panels available, strictly verified by sequence and theoretical MW. |
| Functional Conformation | HEK293 Expressed (Native Glycosylation) for optimal structural fidelity. |
| Lack of Standardization | High Purity (>95%) recombinant enzymes for reproducible kinetic assays. |
| False Positives in Profiling | Sequence-verified siRNA included for precise specificity checks. |
Live UGT1A8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The role of UGT1A8 in drug discovery primarily centers on Phase II drug metabolism and its localized expression in the extrahepatic gastrointestinal tract. As oral therapeutics become more complex, understanding first-pass metabolism mediated by UGT1A8 is critical to preventing dose-limiting toxicities and improving bioavailability. Furthermore, up-regulation of UGT1A8 in certain gastrointestinal cancers presents a mechanism of chemoresistance (e.g., SN-38 glucuronidation), driving a niche but vital market for specific UGT inhibitors as combination therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitors) | Pharma ADME Groups | Bioavailability Enhancement | Selectivity Assay (Need UGT Isoform Panel Proteins) |
| Chemotherapy (Substrates) | Oncology Developers | GI Cancers (Colon) | Metabolic Cleared Assays (Need High-purity Enzymes) |
| Prodrugs | Targeted Delivery Biotechs | Inflammatory Bowel Disease | Enzymatic Conversion Tests (Sequence Verified Targets) |